semaglutide ckd in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial FLOW Study Highlights: How Semaglutide
Description
Using any unlicensed injectable compound carries inherent and serious risks
Similar to liraglutide, semaglutide also interacts with the GLP-1 receptors in the brain to suppress appetite levels and help with weight loss
For more on safe use, read can bacteriostatic water expire
Clinical studies indicate that patients can lose up to 15% or more of their initial body weight after one year of continuous use
